After reviewing the information provided in these studies, we interpreted that the use of SGLT-2 inhibitors is associated with an overall decrease in the rate of cardiovascular outcomes, hospitalizations for heart failure, and associated cardiovascular deaths when used as single-drug therapy or add-on therapy with oGLDs as compared to other anti-diabetic drugs used alone in a real-world scenario. This evidence concerns the gene SLC5A2 and heart failure.